Rosetta Genomics Ltd. (ROSG) Reaches $0.62 52-Week Low; Intuitive Surgical (ISRG) Sentiment Is 1.07

December 6, 2017 - By Dolores Ford

The stock of Rosetta Genomics Ltd. (NASDAQ:ROSG) hit a new 52-week low and has $0.60 target or 4.00% below today’s $0.62 share price. The 8 months bearish chart indicates high risk for the $3.35M company. The 1-year low was reported on Dec, 6 by Barchart.com. If the $0.60 price target is reached, the company will be worth $133,920 less. The stock decreased 12.68% or $0.09 during the last trading session, reaching $0.62. About 456,028 shares traded or 41.76% up from the average. Rosetta Genomics Ltd. (NASDAQ:ROSG) has declined 87.50% since December 6, 2016 and is downtrending. It has underperformed by 104.20% the S&P500.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company has market cap of $42.47 billion. The companyÂ’s da Vinci surgical System translates a surgeonÂ’s natural hand movements, which are performed on instrument controls at a console into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. It has a 48.93 P/E ratio. The Company’s da Vinci surgical system include surgeonÂ’s consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures.

Rosetta Genomics Ltd. operates as a genomic diagnostics firm worldwide. The company has market cap of $3.35 million. The companyÂ’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It currently has negative earnings. It also provides UroVysion, a urine Fluorescence In Situ Hybridization assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH prognostic tests in prostate cancer.

Ratings analysis reveals 67% of Intuitive Surgical’s analysts are positive. Out of 3 Wall Street analysts rating Intuitive Surgical, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $760.0 while the high is $800.0. The stock’s average target of $780 is 105.78% above today’s ($379.04) share price. ISRG was included in 3 notes of analysts from October 13, 2016. The stock has “Buy” rating by Canaccord Genuity on Wednesday, October 19. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, October 19. The rating was initiated by Wells Fargo with “Outperform” on Thursday, October 13.

Analysts await Intuitive Surgical, Inc. (NASDAQ:ISRG) to report earnings on January, 23. They expect $1.91 EPS, up 7.91% or $0.14 from last year’s $1.77 per share. ISRG’s profit will be $214.01 million for 49.61 P/E if the $1.91 EPS becomes a reality. After $2.55 actual EPS reported by Intuitive Surgical, Inc. for the previous quarter, Wall Street now forecasts -25.10% negative EPS growth.

The stock increased 2.58% or $9.54 during the last trading session, reaching $379.04. About 819,726 shares traded or 23.97% up from the average. Intuitive Surgical, Inc. (ISRG) has risen 39.52% since December 6, 2016 and is uptrending. It has outperformed by 22.82% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 1 sale for $2.66 million activity.

Biondo Investment Advisors Llc holds 8.14% of its portfolio in Intuitive Surgical, Inc. for 30,083 shares. Bender Robert & Associates owns 13,293 shares or 7.63% of their US portfolio. Moreover, Cim Llc has 5% invested in the company for 12,483 shares. The New York-based Hudson Valley Investment Advisors Inc Adv has invested 4.62% in the stock. Edgewood Management Llc, a New York-based fund reported 963,731 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>